Characteristics of 2056 participants in the MHCS
| Variable . | No. of participants by HCV, HIV status* . | |||
|---|---|---|---|---|
| HCV+, HIV+ . | HCV+, HIV− . | HCV−, HIV+ . | HCV−, HIV− . | |
| Age, y, median (IQR) | 21 (13-30) | 18 (4-30) | 13 (5-27) | 4 (0-21) |
| Sex (%) | ||||
| Male | 1185 (99) | 600 (96) | 20 (100) | 189 (87) |
| Female | 9 (1) | 24 (4) | 0 | 29 (13) |
| Race/ethnicity (%) | ||||
| White | 1006 (84) | 488 (78) | 15 (75) | 188 (86) |
| Black | 108 (9) | 87 (14) | 5 (25) | 15 (7) |
| Other/missing data | 80 (7) | 49 (8) | 0 | 15 (7) |
| Coagulopathy type (%) | ||||
| Hemophilia A | 916 (77) | 340 (54) | 12 (60) | 111 (51) |
| Hemophilia A, inhibitor | 152 (13) | 100 (16) | 4 (20) | 9 (4) |
| Hemophilia B | 96 (8) | 124 (20) | 2 (10) | 40 (18) |
| Hemophilia B, inhibitor | 5 (< 1) | 2 (< 1) | 0 | 2 (1) |
| Von Willebrand | 9 (1) | 30 (5) | 2 (10) | 30 (14) |
| Von Willebrand, inhibitor | 1 (< 1) | 2 (< 1) | 0 | 0 |
| Other | 6 (1) | 13 (2) | 0 | 23 (11) |
| Missing data | 9 (1) | 11 (2) | 0 | 2 (1) |
| Coagulopathy severity (%) | ||||
| Severe | 979 (82) | 344 (55) | 14 (70) | 57 (26) |
| Moderate | 92 (7) | 108 (17) | 1 (5) | 48 (22) |
| Mild | 114 (10) | 161 (26) | 5 (25) | 111 (51) |
| Missing data | 9 (1) | 11 (2) | 0 | 2 (1) |
| Hepatitis B status (%) | ||||
| Chronic (HBs antigenemia) | 104 (9) | 31 (5) | 3 (15) | 2 (1) |
| Resolved | 987 (83) | 389 (62) | 11 (55) | 50 (23) |
| Uninfected/vaccinated | 91 (8)† | 196 (31)† | 6 (30) | 165 (76) |
| Missing data | 12 (1) | 8 (1) | 0 | 1 (< 1) |
| Variable . | No. of participants by HCV, HIV status* . | |||
|---|---|---|---|---|
| HCV+, HIV+ . | HCV+, HIV− . | HCV−, HIV+ . | HCV−, HIV− . | |
| Age, y, median (IQR) | 21 (13-30) | 18 (4-30) | 13 (5-27) | 4 (0-21) |
| Sex (%) | ||||
| Male | 1185 (99) | 600 (96) | 20 (100) | 189 (87) |
| Female | 9 (1) | 24 (4) | 0 | 29 (13) |
| Race/ethnicity (%) | ||||
| White | 1006 (84) | 488 (78) | 15 (75) | 188 (86) |
| Black | 108 (9) | 87 (14) | 5 (25) | 15 (7) |
| Other/missing data | 80 (7) | 49 (8) | 0 | 15 (7) |
| Coagulopathy type (%) | ||||
| Hemophilia A | 916 (77) | 340 (54) | 12 (60) | 111 (51) |
| Hemophilia A, inhibitor | 152 (13) | 100 (16) | 4 (20) | 9 (4) |
| Hemophilia B | 96 (8) | 124 (20) | 2 (10) | 40 (18) |
| Hemophilia B, inhibitor | 5 (< 1) | 2 (< 1) | 0 | 2 (1) |
| Von Willebrand | 9 (1) | 30 (5) | 2 (10) | 30 (14) |
| Von Willebrand, inhibitor | 1 (< 1) | 2 (< 1) | 0 | 0 |
| Other | 6 (1) | 13 (2) | 0 | 23 (11) |
| Missing data | 9 (1) | 11 (2) | 0 | 2 (1) |
| Coagulopathy severity (%) | ||||
| Severe | 979 (82) | 344 (55) | 14 (70) | 57 (26) |
| Moderate | 92 (7) | 108 (17) | 1 (5) | 48 (22) |
| Mild | 114 (10) | 161 (26) | 5 (25) | 111 (51) |
| Missing data | 9 (1) | 11 (2) | 0 | 2 (1) |
| Hepatitis B status (%) | ||||
| Chronic (HBs antigenemia) | 104 (9) | 31 (5) | 3 (15) | 2 (1) |
| Resolved | 987 (83) | 389 (62) | 11 (55) | 50 (23) |
| Uninfected/vaccinated | 91 (8)† | 196 (31)† | 6 (30) | 165 (76) |
| Missing data | 12 (1) | 8 (1) | 0 | 1 (< 1) |
HBs antigenemia indicates hepatitis B surface antigenemia.
HCV+ and HIV+ indicate infection based on detection of specific antibody, as described in “Materials and methods.” HCV− and HIV− indicate noninfection.
Includes 7 HCV+, HIV+ participants and 15 HCV+, HIV− participants who were vaccinated against hepatitis B.